Two-dose COVID-19 vaccine response works against delta variant, researchers find

New research from France adds to evidence that widely used COVID-19 vaccines still offer strong protection against the delta variant that now accounts for most U.S. infections.

Study results released same day Pfizer says it will seek U.S. authorization for 3rd dose

Two doses of COVID-19 vaccines still offer strong protection against the delta variant that now accounts for most U.S. infections, new research from France indicates. (Sam Nar/CBC)

New research from France adds to evidence that widely used COVID-19 vaccines still offer strong protection against a coronavirus mutant that is spreading rapidly around the world and now is the most prevalent variant in the U.S.

The delta variant is surging through populations with low vaccination rates. On Thursday, Dr. Rochelle Walensky, director of the U.S. Centers for Disease Control and Prevention, said that's leading to "two truths" — highly immunized swaths of America are getting back to normal while hospitalizations are rising in other places.

"This rapid rise is troubling," she said.

A few weeks ago, the delta variant accounted for just over a quarter of new U.S. cases, but it now accounts for just over 50 per cent — and in some places, such as parts of the Midwest, as much as 80 per cent.

Researchers from France's Pasteur Institute reported new evidence Thursday that full vaccination is critical. 

In laboratory tests, blood from several dozen people given their first dose of the Pfizer-BioNtech or AstraZeneca-Oxford vaccines "barely inhibited" the delta variant, the team reported in the journal Nature. But weeks after getting their second dose, nearly all had what researchers deemed an immune boost strong enough to neutralize the delta variant — even if it was a little less potent than against earlier versions of the virus.

The French researchers also tested unvaccinated people who had survived a bout of the coronavirus, and found their antibodies were four-fold less potent against the new mutant. But a single vaccine dose dramatically boosted their antibody levels — sparking cross-protection against the delta variant and two other mutants, the study found. That supports public health recommendations that COVID-19 survivors get vaccinated rather than relying on natural immunity.

The lab experiments add to real-world data that the delta variant's mutations aren't evading the vaccines most widely used in Western countries, but underscore that it's crucial to get more of the world immunized before the virus evolves even more.

There are now even more reasons for Canadians to roll up their sleeves, given that two doses of a COVID-19 vaccine appear to offer strong protection against COVID-19 mutants, whereas a first dose 'barely inhibited' the delta variant. (Mike Segar/Reuters)

Researchers in Britain found two doses of the Pfizer vaccine, for example, are 96 per cent protective against hospitalization with the delta variant and 88 per cent effective against symptomatic infection. That finding was echoed last weekend by Canadian researchers, while a report from Israel suggested protection against mild delta infection may have dipped lower, to 64 per cent.

Whether the fully vaccinated still need to wear masks in places where the delta variant is surging is a growing question. In the U.S., the CDC maintains that fully vaccinated people don't need to. Even before the delta variant came along, the vaccines weren't perfect, but the best evidence suggests that if vaccinated people nonetheless get the coronavirus, they'll have much milder cases.

"Let me emphasize, if you were vaccinated, you have a very high degree of protection," Dr. Anthony Fauci, the U.S. government's top infectious disease expert, said Thursday. 

Pfizer to seek FDA authorization for 3rd-dose booster

Also on Thursday, Pfizer said it plans to seek U.S. authorization for a third dose of its COVID-19 vaccine.

In general, antibodies naturally wane over time, so studies are underway to determine if and when COVID boosters might be needed.

Dr. Mikael Dolsten, Pfizer's chief scientific officer, told The Associated Press that early data from the company's booster study suggests people's antibody levels jump five- to 10-fold after a third dose, compared to their second dose months earlier.

In August, Pfizer plans to ask the U.S. Food and Drug Administration for emergency authorization of a third dose, he said.

But FDA authorization would be just a first step — it wouldn't automatically mean Americans get offered boosters, cautioned Dr. William Schaffner, a vaccine expert at Vanderbilt University Medical Center. Public health authorities would have to decide if they're really needed, especially since millions of people still have no protection as they haven't been vaccinated.

In the U.S., case rates have been rising for weeks and the rate of hospitalizations has started to tick up, rising seven per cent from the previous seven-day average, the CDC's Walensky told reporters Thursday. However, deaths remain down on average, which some experts believe is at least partly due to high vaccination rates in people 65 and older, who are among the most susceptible to severe disease.

Add some “good” to your morning and evening.

A variety of newsletters you'll love, delivered straight to you.

Sign up now